https://www.selleckchem.com/products/ABT-263.html
A total of 210 TAVR patients were included between October 2018 and January 2020. Median age was 81 years, 54% were male, and the median STS score was 2.7%. There was no significant difference in the primary endpoint of access site-related vascular complications between MANTA and ProGlide (10% vs. 4%; p=0.16). Clinically significant access site bleedings were similar with both closure techniques (9% vs. 6%; p=0.57). Modified VCD failure occurred less frequently in MANTA versus ProGlide (20% vs. 40%; p0.01). Suture-based closure requ
Like
Comment
Share
